(Q34106507)

31 July 2017

title

Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients (English)

1 reference

31 July 2017

0 references

1 reference

Lee N

1

1 reference

31 July 2017

Fawaaz R

2

1 reference

31 July 2017

Olsson CA

3

1 reference

31 July 2017

Benson MC

4

1 reference

31 July 2017

Petrylak DP

5

1 reference

31 July 2017

Schiff PB

6

1 reference

31 July 2017

Bagiella E

7

1 reference

31 July 2017

Singh A

8

1 reference

31 July 2017

Ennis RD

9

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

International Journal of Radiation Oncology Biology Physics

31 July 2017

published in

1 reference

31 July 2017

volume

48

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

1443-1446

1 reference

Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

Risk factors for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

The role of bone scanning in the assessment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

Which patients with prostatic carcinoma require a staging bone scan?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

Practice trends in the diagnosis and management of prostate cancer in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2800%2900785-9

7 January 2021

10.1016/S0360-3016(00)00785-9

Identifiers

DOI

1 reference

31 July 2017

1 reference